jRCT2033240611招募中不适用
Open-Label, Dose Escalation, Single-dose Study of RV-001 in Subjects with Retinitis Pigmentosa (Phase I/II)
Restore Vision Inc.0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 15
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
入选标准
- •18 years old and up at the time of ICF signature
- •Diagnosis of non-syndromic Retinitis Pigmentosa
排除标准
- •Diagnosed with an inherited retinal degenerative disease other than non-syndromic Retinitis Pigmentosa or systemic symptoms, such as hearing loss.
- •Prior receipt of any genetic, cell-based or optogenetic therapy for Retinitis Pigmentosa, or prior participation in clinical trials for such therapies.
结局指标
主要结局
-
Dose-Limiting Toxicity
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
CytoMegaloVirus: Alternate donor Study of Pre-Emptive Cellular TherapyISRCTN75391842Cell Medica Ltd (UK)18
进行中（未招募）
1 期
A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantatiorelapsing acute leukemia, relapsing myelodysplastic syndromesMedDRA version: 17.0Level: LLTClassification code 10000835Term: Acute leukemiaSystem Organ Class: 100000004864MedDRA version: 17.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-005446-11-DEGoethe-University Frankfurt40
尚未招募
2 期
Feasibility of ISRT after chemo-immmunotherapy in early nodal DLBCCTRI/2018/03/012340All India Institute of Medical Sciences
招募中
1 期
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCTIS2022-501686-47-00Galapagos25
进行中（未招募）
1 期
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.EUCTR2021-003815-25-ESCellPoint B.V.45